Exclusive usage of Octreotide or combined with celecoxib to prevent and treat with severe acute pancreatitis: a clinical randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000844

Enrollment

Unknown

Registered

2010-01-26

Start date

2010-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe acute pancreatitis

Interventions

combined group (predicted SAP+SAP patients):conventional medical management+octreotide with a syringe pump(50ug/h×3d then 25ug/h×4d )+celecoxib 200mg bid × 7d po.

Control group (predicted SAP+SAP patients):conventional medical management

Low dose octreotide group (predicted SAP+SAP):conventional medical management+octreotide with a syringe pump (25ug/h*7d)

High dose octreotide group (predicted SAP+SAP):conventional medical management+octreotide with a syringe pump (50ug/h*3d then 25ug/h*4d)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with acute pancreatitis: showing obvious upper abdominal pain and serum amylase increased 3 times more than normal maximum level with/without enlargement of pancreas or peripancreatic fluid accumulation;with 2 of the upper symptoms; 2. predicted severe acute pancreatitis: (1) APACHE II score>=8 within 48h from the onset of symptoms; (2) MOF score=2); (2) CTSI>=6; (3) with local complications; 4. Admission within 48h from the onset of symptoms; 5. Age between 18~70 years old; 6. Patients voluntarily signed the informed consent form; 7. Patients did not receive any NSAIDS one month before admission.

Exclusion criteria

Exclusion criteria: 1. Women in pregnancy or lactation; 2. Patients hypersensitive to amindan; 3. Patients with other severe diseases such as: ulcerative colitis, Crohn's disease, cirrhosis, coronary artery disease, chronic obstructive pulmonary disease, malignant tumors,drug abuse, psychinosis et al; 4. Patients with severe diseases of heart, liver,kidnery, endocrine and hemopoietic syetem; 5. Patients with alimentary tract hemorrhage recently.

Design outcomes

Primary

Measure	Time frame
index of radioimmunity;mortality;APACHE II score;Predicted SAP developement into SAP;SAP remission rate;incidence of organ failure;MOF score;incidence of long-term complication;CTSI;	—

Secondary

Measure	Time frame
cost of hospitalization;index of inflammation;time of start eating;length of stay;SIRS score;Drug side effec;	—

Countries

China

Contacts

Public ContactChengwei Tang

cwtang@medmail.com.cn+86 18980601275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026